Working… Menu
Trial record 1 of 5 for:    Regeneron | Diffuse Large B Cell Lymphoma | United States
Previous Study | Return to List | Next Study

Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02290951
Recruitment Status : Active, not recruiting
First Posted : November 14, 2014
Last Update Posted : December 22, 2020
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Brief Summary:
This is an open-label, multi-center, dose escalation study of REGN1979 administered as an IV (intravenous) infusion. This phase 1 study will investigate the safety and tolerability of REGN1979 in patients with B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Condition or disease Intervention/treatment Phase
Non-Hodgkin Lymphoma Chronic Lymphocytic Leukemia Drug: REGN1979 multiple dose levels Drug: Rituximab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 480 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy
Actual Study Start Date : January 9, 2015
Estimated Primary Completion Date : April 17, 2025
Estimated Study Completion Date : April 17, 2025

Arm Intervention/treatment
Experimental: Experimental cohorts N
Experimental cohorts N (participants with CD20+NHL) will receive multiple dose levels of REGN1979 Rituximab lead-in cohort N will receive multiple dose regimens of REGN1979
Drug: REGN1979 multiple dose levels
Administered by intravenous (IV) infusion

Drug: Rituximab
Rituximab will be administered prior to the first dose of REGN1979.

Experimental: Experimental cohorts C
Experimental cohorts C (participants with CLL) will receive multiple dose levels of REGN1979
Drug: REGN1979 multiple dose levels
Administered by intravenous (IV) infusion

Primary Outcome Measures :
  1. Safety/overall frequency of adverse events [ Time Frame: Up to 24 months ]
  2. Antitumor activity as measured by the objective response rate(ORR) [ Time Frame: Through study completion, an average of 24 months ]

    Expansion Cohorts:

    • Diffuse large B-cell lymphoma (DLBCL) after failure of CAR-T therapy
    • Aggressive lymphoma cohorts 1 and 2
    • Follicular lymphoma (FL) grade 1-3a cohorts 1 and 2
    • Rituximab lead-in
    • Chronic lymphocytic leukemia (CLL)

Secondary Outcome Measures :
  1. Pharmacokinetics (Concentration of REGN1979) [ Time Frame: Up to 10 months ]
    Peak plasma concentration (Cmax) of REGN1979

  2. Immunogenicity (Anti-REGN1979 antibodies) [ Time Frame: Up to 15 months ]
    Anti-REGN1979 antibodies

  3. Objective response rate (ORR) [ Time Frame: Through study completion, an average of 24 months ]
    For dose escalation portion and rituximab lead-in dose groups

  4. Progression-free survival [ Time Frame: Up to 48 months ]
  5. Overall Survival [ Time Frame: Up to 48 months ]
  6. Minimal residual disease (MRD) for patients with CLL [ Time Frame: Up to 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  1. Have documented CD20+ B-cell malignancy, with active disease not responsive to prior therapy, for whom no standard of care options exists, and for whom treatment with an anti-CD20 antibody may be appropriate.
  2. Patients with NHL must have had prior treatment with an anti-CD20 antibody therapy. Patients with CLL are not required to have received prior treatment with an anti-CD20 antibody therapy, provided the patient has failed either a BTK inhibitor or PI3K inhibitor and the treating physician deems it appropriate for the patient to be entered into a phase 1 trial.

    • For inclusion in the FL grade 1-3a expansion cohort, patients must have received at least 2 prior lines of systemic therapy, including an anti-CD20 antibody and an alkylating agent.
    • For the inclusion in the disease-specific expansion cohort enrolling DLBCL patients after failure of CAR-T therapy, the patient must have recovered from the toxicities of the lymphodepletion therapy and CAR-T infusion.
  3. Must have at least one bi-dimensionally measurable lesion ≥1.5 cm) documented by CT or MRI scan.
  4. Eastern Cooperative Oncology Group (ECOG) performance status ≤1
  5. Life expectancy of at least 6 months
  6. Adequate bone marrow function documented by:

    1. Platelet counts ≥75 x 10^9/L
    2. Hb level ≥9 g/dL
    3. Absolute neutrophil count (ANC) ≥1 x 10^9/L
  7. Adequate organ function documented by:

    1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 X ULN
    2. Total bilirubin ≤1.5 X ULN
    3. Calculated creatinine clearance by Cockcroft-Gault ≥50 mL/min (patients with borderline creatinine clearance by Cockcroft-Gault may be considered for enrollment if a measured creatinine clearance (based on 24-hour urine or other reliable method) is ≥50 mL/min)
  8. Willing and able to comply with clinic visits and study-related procedures
  9. Provide signed informed consent

Key Exclusion Criteria:

  1. Primary central nervous system (CNS) lymphoma or known or suspected CNS involvement by non-primary CNS NHL
  2. History of or current relevant CNS pathology
  3. Allogeneic stem cell transplantation
  4. Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients with hepatitis B (HepBsAg+) who have controlled infection (serum hepatitis B virus DNA that is below the limit of detection AND receiving anti-viral therapy for hepatitis B) are permitted upon consultation with the physician managing the infection.
  5. Known hypersensitivity to both allopurinol and rasburicase
  6. History of hypersensitivity to any compound in the tetracycline antibiotics group

The information provided above is not intended to contain all considerations relevant to potential participation in a clinical trial therefore not all inclusion/ exclusion criteria are listed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02290951

Layout table for location information
United States, California
University of California, Irvine
Orange, California, United States, 92868
Stanford University
Stanford, California, United States, 94305
United States, Florida
Moffitt Cancer Center
Tampa, Florida, United States, 33612
United States, Massachusetts
Dana Farber Cancer Institute (Massachusetts General Hospital and Beth Israel)
Boston, Massachusetts, United States, 02215
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08901
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Weill Cornell Medical College
New York, New York, United States, 10065
Universitatsklinikum Wurzburg
Wurzburg, Germany
Sponsors and Collaborators
Regeneron Pharmaceuticals
Layout table for investigator information
Study Director: Clinical Trial Management Regeneron Pharmaceuticals
Layout table for additonal information
Responsible Party: Regeneron Pharmaceuticals Identifier: NCT02290951    
Other Study ID Numbers: R1979-HM-1333
2015-004491-30 ( EudraCT Number )
First Posted: November 14, 2014    Key Record Dates
Last Update Posted: December 22, 2020
Last Verified: February 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Regeneron Pharmaceuticals:
Diffuse large B-cell lymphoma (DLBCL)
Follicular lymphoma (FL)
Aggressive lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, Lymphoid
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents